COMMUNIQUÉS West-GlobeNewswire

LifeMD Reports Third Quarter 2024 Results
07/11/2024
Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to $3.7 million [...]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
07/11/2024
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]
Profound Medical Announces Third Quarter 2024 Financial Results
07/11/2024
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
TELA Bio Reports Third Quarter 2024 Financial Results
07/11/2024
Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a [...]
Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results
07/11/2024
GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
The Joint Corp. Reports Third Quarter 2024 Financial Results
07/11/2024
SCOTTSDALE, Ariz., Nov. 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended September [...]
ProPhase Labs Announces Proposed Public Offering of Common Stock
07/11/2024
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell shares of its common [...]
RxSight, Inc. Reports Third Quarter 2024 Financial Results
07/11/2024
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
07/11/2024
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
07/11/2024
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. [...]
Kura Oncology Reports Third Quarter 2024 Financial Results
07/11/2024
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation [...]
PacBio Announces Third Quarter 2024 Financial Results
07/11/2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
07/11/2024
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/ [...]
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance
07/11/2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
07/11/2024
Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectively Received $122 Million of Procurement Orders from the U.S. Government in the Third Quarter Corporate [...]
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
07/11/2024
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First [...]
Rani Therapeutics to Participate in Upcoming Investor Conferences
07/11/2024
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
07/11/2024
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meeting Han Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial [...]
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
06/11/2024
PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced [...]

Pages